Current stock page

Financial Data

EWTX Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

EWTXEdgewise Therapeutics, Inc.

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$45.93+$0.11 (+0.24%)

Latest quote

  • Momentum
    82
  • Value
    —
  • Quality
    68
  • Risk resilience
    57
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$0$0$0$0$0$0$0
Gross Profit$0$0-$590K$0$0$0$0$0
Operating Income-$46.14M-$61.94M-$54.12M-$55.98M-$46.86M-$42.61M-$45.96M-$45.54M
Net Income$1.17B-$57.33M-$49.01M-$50.22M-$40.67M-$36.12M-$40.8M-$39.66M
EPS$10.71-$0.53-$0.46-$0.47-$0.39-$0.34-$0.43-$0.42
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$77.25M-$43.51M-$42.54M-$38.59M-$34.78M-$32.58M-$37.87M-$26.96M
Capital Expenditure-$17K-$32K-$260K-$73K-$89K-$50K-$44K-$274K
Free Cash Flow-$77.27M-$43.54M-$42.8M-$38.67M-$34.87M-$32.63M-$37.91M-$27.23M
Net Cash Provided By Operating Activities-$77.25M-$43.51M-$42.54M-$38.59M-$34.78M-$32.58M-$37.87M-$26.96M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$1.78B$479.69M$518.52M$552.6M$583.47M$613.33M$454.39M$486.82M
Total Debt$3.38M$3.59M$3.79M$3.99M$4.18M$4.37M$4.56M$4.74M
Cash And Cash Equivalents$68.68M$72.32M$33.21M$61.15M$46M$43.4M$49.92M$41.67M
Total Liabilities$147.35M$31.61M$25.32M$30.35M$24.82M$24.26M$24.67M$27.6M
Total Stockholders Equity$1.63B$448.08M$493.2M$522.26M$558.65M$589.07M$429.72M$459.22M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio4.65———————
P/B ratio2.8810.677.735.853.232.313.255.14
P/S ratio————————
Debt To Equity00.010.010.010.010.010.010.01
Free Cash Flow Yield-4.30%-3.34%-3.90%-4.71%-7.36%-9.25%-8.54%-4.68%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio4.65———————
P/B ratio2.8810.677.735.853.232.313.255.14
P/S ratio————————
Return On Equity61.84%-44.02%-35.69%-32.13%-28.15%-25.58%-34.00%-29.14%
Debt To Equity00.010.010.010.010.010.010.01

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe4.97x
Pb3.06x
EPS Growth Yoy2846.15%
Gross Margin0.00%
Operating Margin0.00%
ROE130.43%
ROIC-11.55%
Debt To Equity0
FCF Yield-4.09%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$45.93
Volume1.16M
RSI (14)61.82
MACD1.67
MACD signal0.76
MACD histogram0.91
ADX (14)23.14
SMA (50)$41.33
SMA (200)$37.01
ATR (14)$2.85
Historical volatility (annualized)73.12%
Volume (20-day average)1.73M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score57/100
Beta1.1
Annual volatility73.21%
Max Drawdown-24.96%
Sharpe Ratio1.41
VaR (95%, 1-day)-5.04%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

EWTX Financial Data FAQ

What is Edgewise Therapeutics, Inc.'s revenue?

Edgewise Therapeutics, Inc.'s revenue is one of the core financial data points for EWTX. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Edgewise Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Edgewise Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is EWTX's EPS?

EWTX's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Edgewise Therapeutics, Inc.'s net income?

Edgewise Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Edgewise Therapeutics, Inc. generate?

Free cash flow shows how much cash Edgewise Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Edgewise Therapeutics, Inc. have?

Cash and debt help frame EWTX's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.